1. Home
  2. AKBA vs ALIT Comparison

AKBA vs ALIT Comparison

Compare AKBA & ALIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.42

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Logo Alight Inc.

ALIT

Alight Inc.

HOLD

Current Price

$1.59

Market Cap

826.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
ALIT
Founded
2007
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
729.1M
826.0M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
AKBA
ALIT
Price
$1.42
$1.59
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
5
Target Price
$5.92
$4.70
AVG Volume (30 Days)
3.1M
10.8M
Earning Date
03-12-2026
02-19-2026
Dividend Yield
N/A
10.00%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$225,071,000.00
$2,289,000,000.00
Revenue This Year
$52.41
N/A
Revenue Next Year
$21.57
$1.21
P/E Ratio
N/A
N/A
Revenue Growth
32.49
N/A
52 Week Low
$1.30
$1.46
52 Week High
$4.08
$7.66

Technical Indicators

Market Signals
Indicator
AKBA
ALIT
Relative Strength Index (RSI) 46.10 43.39
Support Level $1.35 $1.46
Resistance Level $1.44 $1.69
Average True Range (ATR) 0.08 0.10
MACD 0.01 0.03
Stochastic Oscillator 42.50 52.17

Price Performance

Historical Comparison
AKBA
ALIT

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About ALIT Alight Inc.

Alight Inc is a technology-enabled services company delivering human capital management solutions to many of complex organizations. This includes the implementation and administration of employee benefits (e.g., health, wealth and leaves benefits) solutions, currently operates under one reportable segment, Employer Solutions. The Company completed the Divestiture of Alight's Professional Services segment and Alight's Payroll & HCM Outsourcing business within the Employer Solutions segment. The company operates in USA states and International market too.

Share on Social Networks: